Ann: Opthea Corporate Presentation - April 2024, page-3

Two important bits that I noticed were:

Slide 3
"COAST enrolment complete as of Feb 2024; ShORe estimated 2Q CY2024 (96% enrolled as of 3 April 2024)"

My thoughts: So we currently have 100% and 96% trial enrolment - that's excellent and means full enrolment very soon. Some patients may be already near to or completing the 12-month trial participation and first results may be starting to come through.

Slide 30
"Concentrated prescriptions in U.S. enables potential self commercialization opportunity with lean and targeted organization"

My thoughts: Does this mean they see themselves going alone to market (without partnership?) because they can and this pathway maximises returns to OPT?

I remain very positive for my investment in OPT.